Biopharmaceutical royalty firm Healthcare Royalty files for a $100 million IPO

Healthcare Royalty, which buys royalty interests in marketed and late-stage biopharmaceuticals, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.

Healthcare Royalty claims it is the leading mid-market royalty acquisition company by number of transactions and aggregate value of capital deployed since 2016. The company's portfolio contains 35 products across 12 therapeutic categories, including Shingrix, Krystexxa, and Xpovio. Since its 2006 inception, Healthcare Royalty has deployed approximately $4.7 billion across 76 royalty-related transactions involving 79 products. 

The Stamford, CT-based company was founded in 2006 and booked $263 million in sales for the 12 months ended March 31, 2021. It plans to list on the NYSE under the symbol HCRX. Goldman Sachs, Citi, Credit Suisse, Jefferies, Cowen, SVB Leerink, Truist Securities, BMO Capital Markets, Stifel, and Raymond James are the joint bookrunners on the deal. No pricing terms were disclosed.